ONCAlert | 2018 ASCO Annual Meeting

Biosimilars MORE >>

Epoetin alfa-epbx (Retacrit) has been approved by the FDA as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. 

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.